A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo (NCT06625177)
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.
Who can join: Review the eligibility criteria below.
Location: Teva Investigational Site 12043 — Scottsdale, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Teva Investigational Site 12043 — Scottsdale, Arizona
- Teva Investigational Site 12052 — Hot Springs, Arkansas
- Teva Investigational Site 12044 — Fremont, California
- Teva Investigational Site 12051 — Irvine, California
- Teva Investigational Site 12046 — Pasadena, California
- Teva Investigational Site 12049 — Miramar, Florida
- Teva Investigational Site 12047 — Chicago, Illinois
- Teva Investigational Site 12053 — Louisville, Kentucky
- Teva Investigational Site 12048 — Canton, Michigan
- Teva Investigational Site 12054 — Portland, Oregon
- Teva Investigational Site 12045 — Dallas, Texas
- Teva Investigational Site 12057 — Webster, Texas
- Teva Investigational Site 12055 — South Jordan, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Vitiligo
- Daily Topical Rapamycin for Vitiligo — Charleston, South Carolina
- A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo — Glendale, Arizona
- A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo — Birmingham, Alabama
- A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo — Encinitas, California
- An Observational Study of Patients With Dermatologic Disease — Winston-Salem, North Carolina
Explore by condition: All Vitiligo clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.